Transdermal clonidine for ameliorating tamoxifen-induced hot flashes

Richard M. Goldberg, Charles L. Loprinzi, Judith R. O'Fallon, Michael H. Veeder, Angela W. Miser, James A. Mailliard, John C. Michalak, Ann Marie Dose, Ken M. Rowland, Nora L. Burnham

Research output: Contribution to journalArticlepeer-review

257 Scopus citations


Purpose: To determine the efficacy of transdermal clonidine for alleviating tamoxifen-induced hot flashes in women with a history of breast cancer. Patients and Methods: A randomized, double-blind, crossover design was used in this prospective study. Women with a history of breast cancer who were receiving tamoxifen and suffering from hot flashes were potentially eligible for this protocol study. Results: Clonidine did reduce hot-flash frequency to a degree that was statistically impressive (P < .0001), but clinically moderate (20% reduction from baseline). It also decreased hot- flash severity (P = .02, 10% reduction from baseline). Clonidine was related to increased mouth dryness (P < .001), constipation (P < .02), itchiness under the patch (P < .01), and drowsiness (P < .05). Conclusion: Better means are needed to alleviate hot flashes among patients in whom estrogen therapy is contraindicated.

Original languageEnglish (US)
Pages (from-to)155-158
Number of pages4
JournalJournal of Clinical Oncology
Issue number1
StatePublished - Jan 1994

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Transdermal clonidine for ameliorating tamoxifen-induced hot flashes'. Together they form a unique fingerprint.

Cite this